Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.
Identifieur interne : 000B76 ( Main/Exploration ); précédent : 000B75; suivant : 000B77Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.
Auteurs : Abdollahi H [Iran] ; Shiri I [Suisse] ; Bevelacqua J J [États-Unis] ; Jafarzadeh A [Iran] ; Rahmim A [Canada] ; Zaidi H [Suisse, Pays-Bas, Danemark] ; Mortazavi S A R [Iran] ; Mortazavi S M J [Iran]Source :
- Journal of biomedical physics & engineering [ 2251-7200 ] ; 2020.
Abstract
Physicians and scientists around the world are aggressively attempting to develop effective treatment strategies. The treatment goal is to reduce the fatality rate in 15% to 20% of individuals infected with SARS-CoV-2 who develop severe inflammatory conditions that can lead to pneumonia, and acute respiratory distress syndrome. These conditions are major causes of death in these patients. Convalescent plasma (CP) collected from patients recovered from the novel corona virus disease (COVID-19) has been considered as an effective treatment method for COVID-19. Moreover, low-dose radiation therapy (LDRT) for COVID-19 pneumonia was historically used to treat pneumonia during the first half of the 20th century. The concept of LDRT for COVID-19 pneumonia was first introduced in March 2020. Later scientists from Canada, Spain, United States, Germany and France also confirmed the potential efficacy of LDRT for treatment of COVID-19 pneumonia. The rationale behind introducing LDRT as an effective treatment method for pneumonia in COVID-19 patients is not only due to its anti-inflammatory effect, but also in optimization of the activity of the immune system. Moreover, LDRT, unlike other treatment methods such as antiviral drugs, does not have the key disadvantage of exerting a significant selective pressure on the SARS-CoV-2 virus and hence does not lead to evolution of the virus through mutations. Given these considerations, we believe that a hybrid treatment including both CP and LDRT can trigger synergistic responses that will help healthcare providers in mitigating today's COVID-19 pandemic.
DOI: 10.31661/jbpe.v0i0.2006-1125
PubMed: 32802787
PubMed Central: PMC7416097
Affiliations:
- Canada, Danemark, Iran, Pays-Bas, Suisse, États-Unis
- Groningue (province), Washington (État)
- Groningue
- Université de Groningue
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.</title><author><name sortKey="H, Abdollahi" sort="H, Abdollahi" uniqKey="H A" first="Abdollahi" last="H">Abdollahi H</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Radiologic Sciences and Medical Physics, Faculty of Allied Medicine, Kerman University of Medical Science, Kerman, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>PhD, Department of Radiologic Sciences and Medical Physics, Faculty of Allied Medicine, Kerman University of Medical Science, Kerman</wicri:regionArea><wicri:noRegion>Kerman</wicri:noRegion></affiliation></author><author><name sortKey="I, Shiri" sort="I, Shiri" uniqKey="I S" first="Shiri" last="I">Shiri I</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 4</wicri:noRegion></affiliation></author><author><name sortKey="J J, Bevelacqua" sort="J J, Bevelacqua" uniqKey="J J B" first="Bevelacqua" last="J J">Bevelacqua J J</name><affiliation wicri:level="2"><nlm:affiliation>PhD, Bevelacqua Resources, Richland, Washington, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PhD, Bevelacqua Resources, Richland, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="A, Jafarzadeh" sort="A, Jafarzadeh" uniqKey="A J" first="Jafarzadeh" last="A">Jafarzadeh A</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Immunology, School of Medicine, Kerman University of Medical Science, Kerman, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>PhD, Department of Immunology, School of Medicine, Kerman University of Medical Science, Kerman</wicri:regionArea><wicri:noRegion>Kerman</wicri:noRegion></affiliation></author><author><name sortKey="A, Rahmim" sort="A, Rahmim" uniqKey="A R" first="Rahmim" last="A">Rahmim A</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Departments of Radiology and Physics, University of British Columbia, Vancouver BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>PhD, Departments of Radiology and Physics, University of British Columbia, Vancouver BC</wicri:regionArea><wicri:noRegion>Vancouver BC</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Integrative Oncology, BC Cancer Research Centre, Vancouver BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>PhD, Department of Integrative Oncology, BC Cancer Research Centre, Vancouver BC</wicri:regionArea><wicri:noRegion>Vancouver BC</wicri:noRegion></affiliation></author><author><name sortKey="H, Zaidi" sort="H, Zaidi" uniqKey="H Z" first="Zaidi" last="H">Zaidi H</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 4</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>PhD, Geneva University Neurocenter, Geneva University, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PhD, Geneva University Neurocenter, Geneva University, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation><affiliation wicri:level="4"><nlm:affiliation>PhD, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>PhD, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>PhD, Department of Nuclear Medicine, University of Southern Denmark, Odense</wicri:regionArea><wicri:noRegion>Odense</wicri:noRegion></affiliation></author><author><name sortKey="S A R, Mortazavi" sort="S A R, Mortazavi" uniqKey="S A R M" first="Mortazavi" last="S A R">Mortazavi S A R</name><affiliation wicri:level="1"><nlm:affiliation>MD, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>MD, School of Medicine, Shiraz University of Medical Sciences, Shiraz</wicri:regionArea><wicri:noRegion>Shiraz</wicri:noRegion></affiliation></author><author><name sortKey="S M J, Mortazavi" sort="S M J, Mortazavi" uniqKey="S M J M" first="Mortazavi" last="S M J">Mortazavi S M J</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Medical Physics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>PhD, Department of Medical Physics, School of Medicine, Shiraz University of Medical Sciences, Shiraz</wicri:regionArea><wicri:noRegion>Shiraz</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32802787</idno><idno type="pmid">32802787</idno><idno type="doi">10.31661/jbpe.v0i0.2006-1125</idno><idno type="pmc">PMC7416097</idno><idno type="wicri:Area/Main/Corpus">000585</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000585</idno><idno type="wicri:Area/Main/Curation">000585</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000585</idno><idno type="wicri:Area/Main/Exploration">000585</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.</title><author><name sortKey="H, Abdollahi" sort="H, Abdollahi" uniqKey="H A" first="Abdollahi" last="H">Abdollahi H</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Radiologic Sciences and Medical Physics, Faculty of Allied Medicine, Kerman University of Medical Science, Kerman, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>PhD, Department of Radiologic Sciences and Medical Physics, Faculty of Allied Medicine, Kerman University of Medical Science, Kerman</wicri:regionArea><wicri:noRegion>Kerman</wicri:noRegion></affiliation></author><author><name sortKey="I, Shiri" sort="I, Shiri" uniqKey="I S" first="Shiri" last="I">Shiri I</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 4</wicri:noRegion></affiliation></author><author><name sortKey="J J, Bevelacqua" sort="J J, Bevelacqua" uniqKey="J J B" first="Bevelacqua" last="J J">Bevelacqua J J</name><affiliation wicri:level="2"><nlm:affiliation>PhD, Bevelacqua Resources, Richland, Washington, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>PhD, Bevelacqua Resources, Richland, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region></placeName></affiliation></author><author><name sortKey="A, Jafarzadeh" sort="A, Jafarzadeh" uniqKey="A J" first="Jafarzadeh" last="A">Jafarzadeh A</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Immunology, School of Medicine, Kerman University of Medical Science, Kerman, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>PhD, Department of Immunology, School of Medicine, Kerman University of Medical Science, Kerman</wicri:regionArea><wicri:noRegion>Kerman</wicri:noRegion></affiliation></author><author><name sortKey="A, Rahmim" sort="A, Rahmim" uniqKey="A R" first="Rahmim" last="A">Rahmim A</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Departments of Radiology and Physics, University of British Columbia, Vancouver BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>PhD, Departments of Radiology and Physics, University of British Columbia, Vancouver BC</wicri:regionArea><wicri:noRegion>Vancouver BC</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Integrative Oncology, BC Cancer Research Centre, Vancouver BC, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>PhD, Department of Integrative Oncology, BC Cancer Research Centre, Vancouver BC</wicri:regionArea><wicri:noRegion>Vancouver BC</wicri:noRegion></affiliation></author><author><name sortKey="H, Zaidi" sort="H, Zaidi" uniqKey="H Z" first="Zaidi" last="H">Zaidi H</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4</wicri:regionArea><wicri:noRegion>CH-1211 Geneva 4</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>PhD, Geneva University Neurocenter, Geneva University, Geneva, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>PhD, Geneva University Neurocenter, Geneva University, Geneva</wicri:regionArea><wicri:noRegion>Geneva</wicri:noRegion></affiliation><affiliation wicri:level="4"><nlm:affiliation>PhD, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>PhD, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName><orgName type="university">Université de Groningue</orgName></affiliation><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark.</nlm:affiliation><country xml:lang="fr">Danemark</country><wicri:regionArea>PhD, Department of Nuclear Medicine, University of Southern Denmark, Odense</wicri:regionArea><wicri:noRegion>Odense</wicri:noRegion></affiliation></author><author><name sortKey="S A R, Mortazavi" sort="S A R, Mortazavi" uniqKey="S A R M" first="Mortazavi" last="S A R">Mortazavi S A R</name><affiliation wicri:level="1"><nlm:affiliation>MD, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>MD, School of Medicine, Shiraz University of Medical Sciences, Shiraz</wicri:regionArea><wicri:noRegion>Shiraz</wicri:noRegion></affiliation></author><author><name sortKey="S M J, Mortazavi" sort="S M J, Mortazavi" uniqKey="S M J M" first="Mortazavi" last="S M J">Mortazavi S M J</name><affiliation wicri:level="1"><nlm:affiliation>PhD, Department of Medical Physics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>PhD, Department of Medical Physics, School of Medicine, Shiraz University of Medical Sciences, Shiraz</wicri:regionArea><wicri:noRegion>Shiraz</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of biomedical physics & engineering</title><idno type="ISSN">2251-7200</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Physicians and scientists around the world are aggressively attempting to develop effective treatment strategies. The treatment goal is to reduce the fatality rate in 15% to 20% of individuals infected with SARS-CoV-2 who develop severe inflammatory conditions that can lead to pneumonia, and acute respiratory distress syndrome. These conditions are major causes of death in these patients. Convalescent plasma (CP) collected from patients recovered from the novel corona virus disease (COVID-19) has been considered as an effective treatment method for COVID-19. Moreover, low-dose radiation therapy (LDRT) for COVID-19 pneumonia was historically used to treat pneumonia during the first half of the 20<sup>th</sup> century. The concept of LDRT for COVID-19 pneumonia was first introduced in March 2020. Later scientists from Canada, Spain, United States, Germany and France also confirmed the potential efficacy of LDRT for treatment of COVID-19 pneumonia. The rationale behind introducing LDRT as an effective treatment method for pneumonia in COVID-19 patients is not only due to its anti-inflammatory effect, but also in optimization of the activity of the immune system. Moreover, LDRT, unlike other treatment methods such as antiviral drugs, does not have the key disadvantage of exerting a significant selective pressure on the SARS-CoV-2 virus and hence does not lead to evolution of the virus through mutations. Given these considerations, we believe that a hybrid treatment including both CP and LDRT can trigger synergistic responses that will help healthcare providers in mitigating today's COVID-19 pandemic.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32802787</PMID><DateRevised><Year>2020</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2251-7200</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of biomedical physics & engineering</Title><ISOAbbreviation>J Biomed Phys Eng</ISOAbbreviation></Journal><ArticleTitle>Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.</ArticleTitle><Pagination><MedlinePgn>387-394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31661/jbpe.v0i0.2006-1125</ELocationID><Abstract><AbstractText>Physicians and scientists around the world are aggressively attempting to develop effective treatment strategies. The treatment goal is to reduce the fatality rate in 15% to 20% of individuals infected with SARS-CoV-2 who develop severe inflammatory conditions that can lead to pneumonia, and acute respiratory distress syndrome. These conditions are major causes of death in these patients. Convalescent plasma (CP) collected from patients recovered from the novel corona virus disease (COVID-19) has been considered as an effective treatment method for COVID-19. Moreover, low-dose radiation therapy (LDRT) for COVID-19 pneumonia was historically used to treat pneumonia during the first half of the 20<sup>th</sup> century. The concept of LDRT for COVID-19 pneumonia was first introduced in March 2020. Later scientists from Canada, Spain, United States, Germany and France also confirmed the potential efficacy of LDRT for treatment of COVID-19 pneumonia. The rationale behind introducing LDRT as an effective treatment method for pneumonia in COVID-19 patients is not only due to its anti-inflammatory effect, but also in optimization of the activity of the immune system. Moreover, LDRT, unlike other treatment methods such as antiviral drugs, does not have the key disadvantage of exerting a significant selective pressure on the SARS-CoV-2 virus and hence does not lead to evolution of the virus through mutations. Given these considerations, we believe that a hybrid treatment including both CP and LDRT can trigger synergistic responses that will help healthcare providers in mitigating today's COVID-19 pandemic.</AbstractText><CopyrightInformation>Copyright: © Journal of Biomedical Physics and Engineering.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>H</LastName><ForeName>Abdollahi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PhD, Department of Radiologic Sciences and Medical Physics, Faculty of Allied Medicine, Kerman University of Medical Science, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>I</LastName><ForeName>Shiri</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J J</LastName><ForeName>Bevelacqua</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>PhD, Bevelacqua Resources, Richland, Washington, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A</LastName><ForeName>Jafarzadeh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>PhD, Department of Immunology, School of Medicine, Kerman University of Medical Science, Kerman, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>A</LastName><ForeName>Rahmim</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>PhD, Departments of Radiology and Physics, University of British Columbia, Vancouver BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PhD, Department of Integrative Oncology, BC Cancer Research Centre, Vancouver BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H</LastName><ForeName>Zaidi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>PhD, Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, CH-1211 Geneva 4, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PhD, Geneva University Neurocenter, Geneva University, Geneva, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PhD, Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PhD, Department of Nuclear Medicine, University of Southern Denmark, Odense, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S A R</LastName><ForeName>Mortazavi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>MD, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S M J</LastName><ForeName>Mortazavi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>PhD, Department of Medical Physics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>J Biomed Phys Eng</MedlineTA><NlmUniqueID>101589641</NlmUniqueID><ISSNLinking>2251-7200</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N"> Anti-Inflammatory Responses</Keyword><Keyword MajorTopicYN="N"> COVID-19</Keyword><Keyword MajorTopicYN="N"> Convalescent Plasma</Keyword><Keyword MajorTopicYN="N"> Immune System</Keyword><Keyword MajorTopicYN="N"> Low Dose Radiation</Keyword><Keyword MajorTopicYN="N"> Mutations</Keyword><Keyword MajorTopicYN="N"> Radiotherapy</Keyword><Keyword MajorTopicYN="N"> Selective Pressure</Keyword></KeywordList><CoiStatement>Conflict of Interest: None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32802787</ArticleId><ArticleId IdType="doi">10.31661/jbpe.v0i0.2006-1125</ArticleId><ArticleId IdType="pii">JBPE-10-4</ArticleId><ArticleId IdType="pmc">PMC7416097</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Emerg Microbes Infect. 2020 Dec;9(1):727-732</Citation><ArticleIdList><ArticleId IdType="pubmed">32196410</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol Sin. 2020 Jun;35(3):266-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32125642</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Public Health. 2020 May;13(5):667-673</Citation><ArticleIdList><ArticleId IdType="pubmed">32340833</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2015 Jan 1;211(1):80-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25030060</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Lett. 2015 Nov 28;368(2):156-63</Citation><ArticleIdList><ArticleId IdType="pubmed">25911239</ArticleId></ArticleIdList></Reference><Reference><Citation>ACS Chem Neurosci. 2020 Apr 1;11(7):995-998</Citation><ArticleIdList><ArticleId IdType="pubmed">32167747</ArticleId></ArticleIdList></Reference><Reference><Citation>Aquat Toxicol. 2016 Dec;181:76-85</Citation><ArticleIdList><ArticleId IdType="pubmed">27821350</ArticleId></ArticleIdList></Reference><Reference><Citation>J Autoimmun. 2020 May;109:102433</Citation><ArticleIdList><ArticleId IdType="pubmed">32113704</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Med Rev. 2020 Apr 23;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32359788</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes Metab Syndr. 2020 Jul - Aug;14(4):407-412</Citation><ArticleIdList><ArticleId IdType="pubmed">32335367</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496</Citation><ArticleIdList><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>Yale J Biol Med. 2013 Dec 13;86(4):555-70</Citation><ArticleIdList><ArticleId IdType="pubmed">24348219</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Imaging Radiat Sci. 2020 Jun;51(2):198-199</Citation><ArticleIdList><ArticleId IdType="pubmed">32340895</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Oral Sci. 2020 Feb 24;12(1):8</Citation><ArticleIdList><ArticleId IdType="pubmed">32094336</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342</Citation><ArticleIdList><ArticleId IdType="pubmed">32202240</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Total Environ. 2020 Jul 10;725:138277</Citation><ArticleIdList><ArticleId IdType="pubmed">32278175</ArticleId></ArticleIdList></Reference><Reference><Citation>Transfus Apher Sci. 2020 Jun;59(3):102790</Citation><ArticleIdList><ArticleId IdType="pubmed">32345485</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2020 Jun;147:221</Citation><ArticleIdList><ArticleId IdType="pubmed">32342871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation><ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Strahlenther Onkol. 2020 Aug;196(8):679-682</Citation><ArticleIdList><ArticleId IdType="pubmed">32388805</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Oncol Rep. 2020 May 8;22(5):53</Citation><ArticleIdList><ArticleId IdType="pubmed">32385672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2020 Jul;158(1):e9-e13</Citation><ArticleIdList><ArticleId IdType="pubmed">32243945</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Microbiol. 2020 Apr;5(4):562-569</Citation><ArticleIdList><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 27;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Radiother. 2020 Jun;24(3):179-181</Citation><ArticleIdList><ArticleId IdType="pubmed">32389579</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biomed Phys Eng. 2020 Apr 01;10(2):241-246</Citation><ArticleIdList><ArticleId IdType="pubmed">32337192</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiother Oncol. 2020 Jun;147:212-216</Citation><ArticleIdList><ArticleId IdType="pubmed">32437820</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Transl Radiat Oncol. 2020 Apr 25;23:27-29</Citation><ArticleIdList><ArticleId IdType="pubmed">32373721</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li><li>Danemark</li><li>Iran</li><li>Pays-Bas</li><li>Suisse</li><li>États-Unis</li></country><region><li>Groningue (province)</li><li>Washington (État)</li></region><settlement><li>Groningue</li></settlement><orgName><li>Université de Groningue</li></orgName></list><tree><country name="Iran"><noRegion><name sortKey="H, Abdollahi" sort="H, Abdollahi" uniqKey="H A" first="Abdollahi" last="H">Abdollahi H</name></noRegion><name sortKey="A, Jafarzadeh" sort="A, Jafarzadeh" uniqKey="A J" first="Jafarzadeh" last="A">Jafarzadeh A</name><name sortKey="S A R, Mortazavi" sort="S A R, Mortazavi" uniqKey="S A R M" first="Mortazavi" last="S A R">Mortazavi S A R</name><name sortKey="S M J, Mortazavi" sort="S M J, Mortazavi" uniqKey="S M J M" first="Mortazavi" last="S M J">Mortazavi S M J</name></country><country name="Suisse"><noRegion><name sortKey="I, Shiri" sort="I, Shiri" uniqKey="I S" first="Shiri" last="I">Shiri I</name></noRegion><name sortKey="H, Zaidi" sort="H, Zaidi" uniqKey="H Z" first="Zaidi" last="H">Zaidi H</name><name sortKey="H, Zaidi" sort="H, Zaidi" uniqKey="H Z" first="Zaidi" last="H">Zaidi H</name></country><country name="États-Unis"><region name="Washington (État)"><name sortKey="J J, Bevelacqua" sort="J J, Bevelacqua" uniqKey="J J B" first="Bevelacqua" last="J J">Bevelacqua J J</name></region></country><country name="Canada"><noRegion><name sortKey="A, Rahmim" sort="A, Rahmim" uniqKey="A R" first="Rahmim" last="A">Rahmim A</name></noRegion><name sortKey="A, Rahmim" sort="A, Rahmim" uniqKey="A R" first="Rahmim" last="A">Rahmim A</name></country><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="H, Zaidi" sort="H, Zaidi" uniqKey="H Z" first="Zaidi" last="H">Zaidi H</name></region></country><country name="Danemark"><noRegion><name sortKey="H, Zaidi" sort="H, Zaidi" uniqKey="H Z" first="Zaidi" last="H">Zaidi H</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B76 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B76 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32802787
|texte= Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32802787" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |